PharmaCielo Announces Appointment of Marc Lustig as Chairman and CEO
Ontario and Rionegro, Colombia--(Newsfile Corp. - July 11, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that Marc Lustig has been appointed Chairman and CEO of PharmaCielo. Mr. Lustig has a proven history of value creation across the cannabis, capital markets and...
2023-07-11 9:00 AM EDT
PharmaCielo Provides Corporate Update
PharmaCielo is actively working with more than 24 customers in 15 countries globally, with a focus on psychoactive APIs and dried flower. The Company recently made its first shipment of THC Distillate and THC-Dominant Dried Flower to a customer in Australia that will be supplying these products to dispensaries across the country. The Company has closed the final tranche of the previously announced non-brokered private placement and announced its plans to issue up to 5,000 debenture units in a...
2023-06-29 7:30 AM EDT
PharmaCielo Announces Q1 2023 Financial Results
Ontario and Rionegro, Colombia--(Newsfile Corp. - May 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("Pha
2023-05-29 7:30 AM EDT
PharmaCielo Announces Shipment of Pharmaceutical Grade Cannabis Extract to Customer in South Africa
Ontario and Rionegro, Colombia--(Newsfile Corp. - May 16, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has made an initial shipment of CBD Isolate to a specialty biotechnology company based in South Africa that specializes in offering GMP certified private...
2023-05-16 7:30 AM EDT
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2022
During 2022, PharmaCielo made shipments to 23 clients in 9 countries, with continued growth expected for 2023. The Company's measured investments in revenue-generating sales channels resulted in revenues of $5.3 million in 2022, almost three-times more than the $1.9 million reported in 2021. Consistent progress on streamlining the business, to move toward profitability - 2022 SG&A expenses represent a 40% reduction vs. 2021, and were 65% lower compared to 2020. PharmaCielo's previously...
2023-05-01 7:30 AM EDT
PharmaCielo Announces Strategic Partnership with CANNPRISMA to Supply EU-GMP Certified Dried Flower to the European Medicinal Cannabis Market
Ontario and Rionegro, Colombia--(Newsfile Corp. - April 19, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has partnered with CANNPRISMA - PHARMA, LDA ("CA
2023-04-19 7:30 AM EDT